- Conditions
- Macular Degeneration
- Interventions
- rhuFab V2 (ranibizumab)
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 70
- States / cities
- Tucson, Arizona • Beverly Hills, California • Irvine, California + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Presumed Ocular Histoplasmosis (POHS)
- Interventions
- ranibizumab, verteporfin
- Drug
- Lead sponsor
- Barnes Retina Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • St Louis, Missouri
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab (Lucentis), 0.5mg ranibizumab
- Drug
- Lead sponsor
- David M. Brown, M.D.
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Age-Related Macular Degeneration
- Interventions
- reduced fluence photodynamic therapy with Visudyne, Lucentis
- Drug
- Lead sponsor
- Barnes Retina Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Age-Related Maculopathy, Choroidal Neovascularization
- Interventions
- Ranibizumab, Verteporfin
- Drug
- Lead sponsor
- Oklahoma State University Center for Health Sciences
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab, Ranibizumab plus Photodynamic therapy
- Drug
- Lead sponsor
- Illinois Retina Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Oak Park, Illinois
- Conditions
- Age Related Macular Degeneration
- Interventions
- ranibizumab, dexamethasone and verteporfin, Ranibizumab
- Drug
- Lead sponsor
- Bay Area Retina Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more
- Conditions
- Exudative Age Related Macular Degeneration
- Interventions
- Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
- Drug · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- ranibizumab 0.5 or 2.0 mg/0.05 cc
- Drug
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- verteporfin, ranibizumab, dexamethasone
- Drug
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more